retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I share your take on the unhappy choice tossed at share holders. Ask what PT would have wanted for his discoveries at this juncture. For those of us who knew him and enjoyed personally sharing his enthuasism, should we abandon the patents? I am not free yet to move in that direction. Although he wasn't disposed to show stress, I feel the dose switch in clinical trials and BOD performance took its toll. I'm here for the science, his lab, and his belief in getting close to a cure.
Stone, as a UTSW friend and PPHM investor, I am aware that department labs compete briskly for research dollars within and outside of the UT system. This isn't news and Texas news organizations do a fair job connecting the dots between Texas Politics and research funding. However, since the CSM ordeal for PPHM investors and hope filled patients, my capacity for trust has thinned to the point I will keep an even sharper eye. It won't hurt to keep an ever watchful eye since PT has left that job to us. Good reading and research!
PGG, I can see UTSW from my house. From my house I can hear of strategies calculated to secure funding from prized sources. I can see unattractive competition. I fret over lab behaviors with regard to the one of most interest to us.
There are other entertaining puzzle pieces to be mined from investigative reporting in TX newspapers after you finish PPHM's puzzle......other pieces, as juicy as they are, don't quite touch PPHM.
J is for JUST A MINUTE! PPHM can't take anything for granted esp. now. In the mix of cancer research start ups associated with UTSWM there is hyper eagerness, unbridled reaching to be head of the pack. Can't hurt to be alert.
ASCO discussion of new approaches next on CNBC.
To answer your question, tarvacin, I asked the blog site and expect to hear, but not when. At least NCI has bavi fully covered by Brekken's webinar.
Reactivating Your Immune System to Fight Cancer
May 27, 2014 | Michelle Liew
Print
On Wednesday, May 28, 2014, Rolf Brekken, Ph.D., an associate professor in the departments of surgery and pharmacology at UT Southwestern Medical Center, will provide information on how cancers evade the immune system and what treatments and combination of treatments, including bavituximab and other immune activators, can be used to reactivate your immuno-suppressed tumor to effectively fight cancer.
This 45-minute online webinar, which is part of the Cancer Research Institute's Breakthroughs in Cancer Immunotherapy webinar series, and generously supported by Peregrine Pharmaceuticals, Inc., is free to the public, but registration is limited, so sign up now.
This 45-minute online webinar, which is part of the Cancer Research Institute's Breakthroughs in Cancer Immunotherapy webinar series, is free to the public, but registration is limited, so sign up now. - See more at: http://cancerresearch.org/news-publications/our-blog/march-2014/can-the-immune-system-see-colorectal-cancer#sthash.foQe1yw4.dpuf - See more at: http://www.cancerresearch.org/news-publications/our-blog/may-2014/reactivating-your-immune-system-to-fight-cancer#sthash.SOrgnnHq.dpuf
No relation. Francis Collins is originally from Staunton, Va.
Yes, that is the company. I found it odd at the time that Phil Thorpe and his lab were not mentioned at all in the DMN article as an example of cancer research considering UTSW was already the beneficiary of his world recognized work. Until now I couldn't imagine ruthless academic competition in this special UTSW field although, of course, I am all too aware that it exists ......just not with regard to Thorpe's work.
I am suggesting we should know all that's going on at UTSW. I am a long since first shares @ $.35 15 yrs. ago. I recognize some of you from Raging Bull days. I discovered Phil Thorp's amazing work by accident while researching MS at UTSW in late 90s. As an investor, I have dismissed sabotage talk until posters here forcefully suggested otherwise. Now, I am suggesting that PPHM, after being tripped up once, be careful as the company moves forward. I am close to the university, sit on a board of visitors, and have a wide view of planning and associated people here and in Austin. I have been in PT's lab and PT personally hand held my family while I was in chemo four yrs. ago in the building next to his lab. I am pretty familiar with UTSW and if I have been peeked with a tiny concern, due diligence here might be in order.
BPs are rummaging around looking for success on the cheap.
Quote: FierceBiotech
"In biomedical research, imitation is now the sincerest form of competition. If heart drugs prove too expensive and too risky to develop, R&D teams and the corporations that fund them steer away. If targeted cancer drugs are winning approvals and the science is well understood, you can expect a host of copycat efforts. And the trend is starting to alarm some analysts who see too many biopharma companies trying to compete for a piece of the same small therapeutic franchises.
Take ALK-positive non-small cell lung cancer, which accounts for a fragment of that market. Pfizer ($PFE) pioneered Xalkori for ALK-positive NSCLC in 2011. Now Roche ($RHHBY) and Novartis ($NVS) are trying to muscle in with their own drugs, RG7853 and LDK378. And Reuters counts 6 more drugs that are in the pipeline with the same target.
Signs of overcrowding--particularly in the cancer R&D field--have begun to cause analysts at Barclays to fret about what will happen once a variety of drugs start competing for the same healthcare buck.
Reuters' Caroline Copley hit on a growing meme in the R&D community. There are clear signs that drug R&D productivity over the last four years has declined, delivering products that are less and less likely to carve out as many dollars as had been projected when they were in development. Copley incorrectly asserts that 2013 approvals were at a "healthy" level--with new approvals dropping to 27 from 39 in 2012, the level of approvals was anything but healthy. But if you combine a meager level of approvals with a trend toward overcrowding the most promising drug targets, you have an even uglier picture for the R&D field to contemplate.
Reuters goes as far as to say that the same problem is now even apparent in the immunotherapy field, with too many companies chasing PD-1 and PD-L1. With three companies in hot pursuit of the first approval, that may be stretching the numbers a bit. But if everybody else jumps in, which is quite likely, then you can expect many more such stories along the same line.
......."sooner or later the beans will be spilling"]
in the meantime r622, all good Longs are hanging in there ...... although ownership of PPHM makes one want to climb the walls some times.
Thanks. I'm still here from the $0.35 cents dazes and the $16 dazes and sticking with it b/c I know the science will work!
Me thinks today is my big dumb day!
You are correct: 4 PM ET for a respectful moment......this is simply a suggestion for the IH bd.
TIME ZONE CENTRAL 3 PM, 1 PM Pacific, 12 Noon ET,
A moment of silence today at 3 PM respecting the loss of Phil Thorpe's insight and energy.
Cause of PT's death: Sudden heart attack at home ...emergency response was quick, but nothing could reverse the catastrophic attack. There was an awful struggle to bring him back to no avail at the hospital. UTSW several weeks later had a large memorial service. I think everyone is still numb from the shock and loss. APB
Jake, PPHM bod, at this time, is a significant impediment. Where are the quantitative degrees, the reputation for straight dealing, and the ability to inspire confidence with II? Study the early formation of HP to spot the weaknesses. Dr.PT probably was very stressed and the anniversary of his death is upon us. I have been thru Raging Bull, FROOTIE, Golfdad, Terry and the rest and our valuation early on at $50pps has IMO tremendously increased. Bod get a grip or better still, give up your grip and move to a higher ground. GL everybody, APB
CJ, may you be comforted and uplifted today as you face the dreaded task of laying God's Servant Diane to rest in eternal peace. Your support and generosity on this board continues to unite us all in the fight to save precious lives. APB
PT was generous with his time, appreciated newbies, invited them to the lab, and introduced them around. He certainly would have welcomed you. Life goes on, but for his grieving friends and colleagues, it is a distasteful task to be on campus, look at his building knowing a cheerful, elegant friend is missing.
What happened to the Aruba plan?
Rx for FEAR = "Whistle a Happy Tune" . Rx for CP's post is putting it to Sondheim's "I'm Still Here."
OT He would love this. Phil was as proud of his antique piano as he was sure of his discovery.